[1] |
Sheehan M, Tanimu S, Tanimu Y, et al. Cinacalcet for the treatment of humoral hypercalcemia of malignancy: An introductory case report with a pathophysiologic and therapeutic review[J]. Case Rep Oncol, 2020, 13(1):321-329.
doi: 10.1159/000506100
pmid: 32308599
|
[2] |
邱小亮, 姚晨姣. 血液肿瘤相关性高钙血症的临床特点及预后因素分析[J]. 暨南大学学报(自然科学与医学版), 2021, 42(3):270-275.
|
[3] |
O'Callaghan S, Yau H. Treatment of malignancy-associated hypercalcemia with cinacalcet: A paradigm shift[J]. Endocr Connect, 2021, 10(1):R13-R24.
doi: 10.1530/EC-20-0487
pmid: 33289687
|
[4] |
Ohneck A, Rosenkaimer S, Sieburg T, et al. Pmgnostic impact of pretherapeutic hemoglobin levels on all-cause mortality in cardiooncology[J]. Anticancer Research, 2021, 41(1):369-378.
doi: 10.21873/anticanres.14785
URL
|
[5] |
毕亚珍, 冯洒然, 李红, 等. 以高钙血症为首发表现的成人急性髓系白血病1例报告[J]. 山东大学学报(医学版), 2021, 59(5):116-118.
|
[6] |
周宏宇, 李浩然, 程玺. 11例卵巢高钙血症型小细胞癌临床分析并文献复习[J]. 中国癌症杂志, 2021, 31(2):136-138.
|
[7] |
Lu B, Shi H. An in-depth look at small cell carcinoma of the ovary, hypercalcemic type (SCCOHT): Clinical implications from recent molecular findings[J]. J Cancer, 2019, 10(1):223-237.
doi: 10.7150/jca.26978
pmid: 30662543
|
[8] |
Hohneck A, Rosenkaimer S, Sieburg T, et al. Prognostic impact of pretherapeutic hemoglobin levels on all-cause mortality in cardiooncology[J]. Anticancer Res, 2021, 41(1):369-378.
doi: 10.21873/anticanres.14785
pmid: 33419833
|
[9] |
Mousseaux C, Dupont A, Rafant C, et al. Epidemiology, clinical features, and management of severe hypercalcemia in critically ill patients[J]. Ann Intensive Care, 2019, 9(1):133.
doi: 10.1186/s13613-019-0606-8
pmid: 31776814
|
[10] |
王辉, 丁霏, 罗薇, 等. 住院患者高钙血症的病因分析[J]. 国际检验医学杂志, 2019, 40(15):1811-1813.
|
[11] |
Chen YP, Wu ZJ, Liu W, et al. Clinicopathological characteristics of adult T cell leukemia/lymphoma[J]. Zhonghua Bing Li Xue Za Zhi, 2019, 48(1):11-16.
|
[12] |
Zarrabi K, Masic S, Schaefer C, et al. Neoadjuvant checkpoint inhibition inrenal cell carcinoma associated Stauffer’s syndrome[J]. Urol Case Rep, 2020, 29:101077.
|